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Abstract
Background
Few data on HIV resistance in pregnancy are available from Mozambique, one of the coun-
tries with the highest HIV toll worldwide. Understanding the patterns of HIV drug resistance
in pregnant women might help in tailoring optimal regimens for prevention of mother to child
transmission of HIV (pMTCT) and antenatal care.
Objectives
To describe the frequency and characteristics of HIV drug resistance mutations (HIVDRM)
in pregnant women with virological failure at delivery, despite pMTCT or antiretroviral ther-
apy (ART).
Methods
Samples from HIV-infected pregnant women from a rural area in southern Mozambique
were analysed. Only women with HIV-1 RNA >400c/mL at delivery were included in the
analysis. HIVDRM were determined using MiSeq® (detection threshold 1%) at the first ante-
natal care (ANC) visit and at the time of delivery.
Results
Ninety and 60 samples were available at the first ANC visit and delivery, respectively. At first
ANC, 97% of the women had HIV-1 RNA>400c/mL, 39% had CD4+ counts <350 c/mm3
and 30% were previously not on ART. Thirteen women (14%) had at least one HIVDRM of
whom 70% were not on previous ART. Eight women (13%) had at least one HIVDRM at
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delivery. Out of 37 women with data available from the two time points, 8 (21%) developed
at least one new HIVDRM during pMTCT or ART. Twenty seven per cent (53/191), 32% (44/
138) and 100% (5/5) of the mutations that were present at enrolment, delivery and that
emerged during pregnancy, respectively, were minority mutations (frequency <20%).
Conclusions
Even with ultrasensitive HIV-1 genotyping, less than 20% of women with detectable viremia
at delivery had HIVDRM before initiating pMTCT or ART. This suggests that factors other
than pre-existing resistance, such as lack of adherence or interruptions of the ANC chain,
are also relevant to explain lack of virological suppression at the time of delivery in women
receiving antiretrovirals drugs during pregnancy.
Introduction
Women are disproportionately vulnerable to HIV infection, particularly in sub-Saharan Africa
(SSA), where approximately three-quarters of new infections are in women of reproductive
age [1]. HIV infection in pregnancy has important public health consequences; it is responsible
for the majority of new HIV pediatric infections and a significant cause of maternal mortality
[2, 3]. Mother to child transmission of HIV (MTCT) can occur during pregnancy, labor and
through breastfeeding [4, 5]. Among the many factors that have been suggested to increase the
risk of MTCT, maternal HIV viral load at delivery has been shown to be the strongest predic-
tor [6, 7]. Provision of antiretroviral (ARV) drugs in pregnancy is the most effective interven-
tion for blocking viral replication and reducing MTCT and HIV/AIDS maternal related deaths
[1, 8]. However, in low-income countries, increasing occurrence of HIV drug resistance muta-
tions (HIVDRM) to first line recommended ARV drugs either for prevention of MTCT
(pMTCT) or antiretroviral therapy (ART) and cross resistances to second line ARV drugs
have been found [9]. Pre-existence of transmitted drug resistant viruses or selection of ARV
drug resistance during pregnancy, may hinder the long-term efficacy of MTCT preventive
programs, as well as severely constrain future treatment options for both mother and child.
Mozambique is one of the 10 countries with the highest HIV prevalence in the world [10].
A study showed that 90% of the subjects on ART with virological failure had developed resis-
tance to first-line treatment options [11]. In addition, a prevalence of 12% of acquired
HIVDRM was reported in HIV infected Mozambican children [12]. However, little informa-
tion on HIV resistance in pregnancy has been reported in the country. As ART coverage con-
tinues to grow, better knowledge of the effectiveness of first line ARV drugs in HIV-infected
pregnant women in Mozambique is key for antenatal care (ANC) and pMTCT programme
optimization and planning. We describe here the frequency and characteristics of HIVDRM,
at first ANC visit and at the time of delivery, in pregnant women participating in a clinical trial
on malaria prevention in Southern Mozambique.
Materials and methods
Study design
This is an observational study to describe the prevalence of HIVDRM at first ANC visit and at
delivery in HIV-infected pregnant women, who were enrolled, from March 2010 to April
2012, in a randomized controlled clinical trial to evaluate the safety and efficacy of MQ
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compared to placebo for malaria prevention (ClinicalTrials.gov, NCT0081121, and Pan Afri-
can Clinical Trials, PACTR2010020001429343) [13].
Study area and population
The study was carried out in Manhic¸a, a semi-rural area in southern Mozambique. Since 1996,
the Centro de Investigac¸ao em Sau´de de Manhic¸a (CISM) is conducting a continuous demo-
graphic surveillance in the Manhic¸a District that covers a population of approximately 95,000
inhabitants in an area of 500km.2 [14]. Although the countrywide HIV average prevalence fig-
ure is 11% a community based study in adults undertaken in the Manhic¸a area in 2012
reported nearly 40% of HIV prevalence, while 30% of pregnant women attending the ANC
were HIV seropositive [15, 16]. The predominantly subtype in the area is subtype C [17, 18].
At the time of this study, pMTCT relied on ARV prophylaxis, which consisted in antepartum
monotherapy with zidovudine (AZT), a single dose nevirapine (sd NVP) at the onset of labor,
and AZT + lamivudine (3TC) at delivery and for 7 days postpartum. National guidelines rec-
ommended ART to HIV-infected pregnant women for their own health if CD4+T cell count
were<350 and/or 3–4 HIV/AIDS WHO clinical stage. The recommended first-line regimen
consisted in the dual NRTI backbone (3TC and either AZT or stavudine [d4T]) plus an NNRTI
(either NVP or efavirenz [EFV]). However, in 2013, Mozambique adopted “Option B+”, con-
sisting in the initiation of lifelong ART with tenofovir (TDF) + 3TC + EFV in all HIV-positive
pregnant and lactating women regardless of their immune status and clinical stage [19]. Both
currently and at the time of the study, to assess intra-utero and perinatal MTCT national guide-
lines recommend to perform an HIV-DNA PCR test between 4–6 weeks of age in all infants
born to HIV-infected mothers, with a confirmatory test on a new sample in those infants who
test positive.
Study procedures
Enrolment of pregnant women. Pregnant women attending the ANC clinics for the first
time were screened for eligibility to participate in the trial. Inclusion criteria were, permanent
residency in the area, a gestational age28 weeks, a positive HIV test, absence of history of
allergy to intervention drugs, absence of history of severe renal, hepatic, psychiatric, or neuro-
logical disease, and no MQ or halofantrine treatment in the preceding four weeks. Following
national guidelines, HIV status was assessed after voluntary HIV counseling. Hemoglobin
(Hb) and the syphilis rapid plasma reagin test (RPR) were also assessed at this visit as part of
routine ANC. Socio-demographic and clinical characteristics were recorded on standardized
questionnaires and five mL of venous blood was collected for CD4+T cell count and HIV viral
load determination. Administration of ARV drugs for pMTCT or for ART was registered in
the study concomitant medication forms.
Following physical examination, enrolled women with gestational age13 weeks received
the first administration of IPTp (either placebo or MQ) under supervision. The second and
third administrations of IPTp-MQ/placebo were given in the next ANC visits at least one
month apart. All women also received study CTXp tablets for daily prophylaxis.
Follow-up of pregnant women and their children. Women were followed-up through
study visits during pregnancy, delivery and up to one month post-partum. At delivery, a sam-
ple from the mother’s peripheral blood was collected for Hb, CD4+T cell count, HIV viral load
and malaria infection evaluation. Following national guidelines for pMTCT of HIV, a capillary
blood sample was collected from the infant at six weeks of age for HIV PCR analysis to assess
vertical transmission.
Antiretroviral drug resistance in pregnant women in Mozambique
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Laboratory methods
HIV serostatus was assessed using rapid test (Determine, Abbot Laboratories, USA), and posi-
tive results confirmed using Unigold rapid test (TM HIV, Trinity Biotech, Ireland), following
national guidelines. HIV-1 RNA levels were determined from cryopreserved plasma samples
using the COBAS AMPLICOR or AmpliPrep (Roche Diagnostics, Rotkreuz, Switzerland)
devices; these assays have a lower detection limit ranging from 50 to 400 copies/mL. CD4+ T
cell counts were determined by flow cytometry after staining of whole blood for CD3, CD8,
CD4 and CD45 using fluorochrome-labelled antibodies and acquisition using FACSCalibur
(BD Biosciences) and Trucount tubes (Becton Dickinson, San Jose, CA, USA). Remaining
plasma samples from first ANC and delivery visits were stored at the CISM laboratory at -80 C˚.
Analysis of genotypic drug resistance of HIV in stored plasma samples was attempted in all
subjects who had HIV-1 RNA400 copies/mL at delivery. HIV-1 RNA was extracted from
140 mL of plasma (QIAamp Viral RNA Mini Kit,Qiagen). Pol amplicons (PR/RT) were PCR-
generated, fragmented using Nextera-XT and sequenced in an Illumina MiSeqTM [20]. Next-
Generation Sequencing (NGS) raw data was analyzed using an in-house pipeline (https://www.
paseq.org). Briefly, we filtered low quality and potentially contaminant sequences and aligned
them against a user-specified reference (NCBI Accesion: 97ZA012) using BWA. Codon-level
variant calling was then performed on the resulting alignments and an amino acid variant table
was generated using a 1% user specified detection threshold with a median of 5147 depth of cov-
erage (IQR: 3295–7281). Drug resistance-associated mutations in protease and reverse tran-
scriptase gene regions from all quality-assured sequences were interpreted with the Standford
HIV database (HIVdb) program. To predict susceptibility to NRTIs, NNRTIs and PIs a resis-
tance score was calculated as susceptible, intermediate level and high level following the Stan-
ford HIVdb scoring system (http://hivdb.stanford.edu).
Data management, statistical methods, and definitions
Data were double-entered using the OpenClinica EnterpriseTM software for clinical data man-
agement (www.openclinica.com).
Literacy was defined as knowing how to read and/or write. Adolescent women were consid-
ered those<19 years of age. CD4+T cell count was categorized as< 350 or > = 350 cells/μl.
Detectable viral load was defined as HIV-1 RNA levels400copies/mL. HIV drug resistance
was considered as the presence of one or more major resistance mutations as defined by the
Stanford HIVdb.
Baseline characteristics of study patients were described using standard statistics. Propor-
tions for categorical variables were assessed using the Chi-squared test or Fisher’s exact test
where appropriate. Student’s t-test or the Mann–Whitney test was used for comparing means
and medians of quantitative variables according to variable characteristics. All statistical tests
were two-tailed and statistical significance was defined as p<0.05. Data analysis was performed
using Stata version 13 (Stata Corp., College Station, TX, US).
Ethics statement and participants’ safety
This is an exploratory analysis nested in a clinical trial, which protocol and informed consent
forms were reviewed and approved by the Ethics Committees from the Hospital Clı´nic of Bar-
celona (Spain) and the local regulatory authorities and National Ethics Review Committee
from Mozambique (209/CNBS/2014). Study participants signed a written informed consent
form prior to enrolment. The study was conducted under the provisions of the Declaration of
Helsinki and in accordance with Good Clinical Practices guidelines set up by the WHO and by
the International Conference of Harmonization. The protocol for the HIV resistance analysis
Antiretroviral drug resistance in pregnant women in Mozambique
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in samples of women participating in the trial was reviewed and approved by the National Eth-
ics Review Committee from Mozambique.
Results
Study profile
Out of 561 enrolled HIV-infected pregnant women, 246 had detectable viral load (HIV-1 RNA
400 copies/ml) at delivery. Out of these 246 women, there were available stored plasma sam-
ples from the first ANC and the delivery from 238 women. Out of these 476 plasma samples,
63 had insufficient plasma volume, and in 263 plasma samples RNA could not be amplified.
Overall, RNA was successfully amplified in samples from 113 women, and were thus, the study
population for this exploratory analysis; 53 women had samples amplified only at enrolment,
23 only at delivery and 37 at both time points (Fig 1).
Out of these 113 women, 18 (16%) were adolescents, 33 (29%) were illiterate and the
median gestational age was 22 weeks, Interquartile Range, (IQR) 17–24. Twenty three (20%) of
the women were primigravidae, 44 (39%) had CD4+ T-cell counts <350 cells/mm3 and almost
all [109 (96%)] had detectable viral load at enrolment. Thirty five women (31%) were on previ-
ous ART with first line regime at the time of enrolment (Table 1).
Fig 1. Study profile.
https://doi.org/10.1371/journal.pone.0196451.g001
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HIV drug resistance mutations at enrolment
Ninety pregnant women at enrolment were included in this part of the analysis. The median
age was 25 years (IQR 21; 29), and the median gestational age 21 weeks (IQR 16; 23). Twenty
one (23%) women were primigravidae, 29 (32%) were illiterate and 15 (17%) were adolescents.
Nearly all women [87 (97%)] had detectable viral load with a median viral load of 47,877 cop-
ies/ml (IQR 12,807–140,129) In 35 (40%) of them, CD4+ T-cell counts were <350 cells/mm3.
Only 27 women (30%) were on ART at the time of the first ANC (Table 2). Thirteen (14%)
presented at least one HIVDRM, 6 (7%) had resistance to NNRTI, 8 (9%) to NRTI and 2 (2%)
to PI. Among the women with at least one HIVDRM, seven (8%) had resistant mutations to
at least one drug of the first-line regimen recommended at the time of the study (Table 3).
Among the women with HIVDRM to NRTI, 4 (4%) had resistant mutations to ddI, 4 (4%) to
TDF and 4 (4%) to 3TC. Of the women who had resistant mutations to NNRTI, 6 (7%) were to
EFV, 6 (7%) to NVP and 2 (2%) to RPV (Table 4). The most frequent mutations are shown in
Table 5. No significant differences were observed in baseline characteristics between women
who presented at least one HIVDRM and those who did not (Table 2).
HIV drug resistance mutations at delivery
There were 60 women included in the analysis at the time of delivery. The median viral load
was of 34943 copies/ml (IQR: 12891–78116), and it was significantly higher in the women
who presented HIVDRM (p = 0.024) (Table 2). Twenty five women (42%) had CD4+ T cell
counts < 350 cells/mm3. Forty six (82%) women had received ARV drugs for pMTCT and 8
(12%) were on ART for their own health during this pregnancy. Four women (7%) had
received neither pMTCT nor ART during this pregnancy. None of the women presenting
HIVDRM at delivery transmitted HIV to their infants at first month of age (Table 2). Eight
women (13%) presented at least one HIVDRM, 5 (8%) to NNRTIs and 6 (10%) to NRTIs.
None of the women had mutations conferring resistance to PIs (Table 3). Among the women
presenting HIVDRM to NNRTI, 5 (8%) women had resistant mutations to NVP, 4 (7%) to
EFV, 2 (3%) to RPV and 2 (3%) to ETR. Of the women with HIVDRM to NRTI, 3 (5%) had
Table 1. Baseline characteristics at enrolment of study participants (N = 113).
Characteristics n %
Age, median (IQR) 25 [21–30]
Adolescents1 18 15.93
Gestational age, median (IQR)2 22 [17–24]
3rd trimester 10 8.85
Primigravidae 23 20.35
Number of previous pregnancies, median (IQR) 2 [1–3]
Illiteracy3 33 29.20
HIV-1 RNA (copies/mL) median (IQR) 35660 [9821–118467]
Detectable HIV-1 RNA 4 109 96.46
CD4+ T-cell counts (cell/mm3), median (IQR) 342 [196–559]
CD4+ T-cell counts <350 cell/mm3 44 38.94
Previously on antiretroviral therapy 35 30.97
1 Age<19 years
2 Gestational age calculated from fundal height
3 Not being able to read and/or write
4 HIV-1 RNA>400 copies/ml
https://doi.org/10.1371/journal.pone.0196451.t001
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resistant mutations to ddI, 3 (5%) to FTC, 3 (5%) to 3TC, 2 (3%) to TDF, 1 (2%) to ABC and 1
(2%) to d4T (Table 4). The most frequent HIVDR mutations are shown in Table 5.
HIV drug resistance mutations at enrolment and at delivery
Thirty seven women had plasma samples from both enrolment and delivery available for this
analysis. Of these, 5 (14%) developed new drug resistances during this pregnancy, though only
Table 2. Characteristics of women at enrolment and at delivery.
Characteristics Enrolment Delivery
All (N = 90) At least one
HIVDRM1
(N = 13)
No HIVDRM1
(N = 77)
P-value All (N = 60) At least one
HIVDRM1
(N = 8)
No HIVDRM1
(N = 52)
P-value
n % n % n % n % n % n %
Characteristics at enrolment
Age2,3 25 [21–29] 26 [19–29] 25 [21–29] 0.895 26 [22–30] 28 [25–31] 26 [22–30] 0.290
Adolescents3 15 16.67 3 23.08 12 15.58 0.449 9 15.00 0 0.00 9 17.31 0.339
Gestational age2,4 21 [16–23] 20 [12–22] 21 [16–23] 0.468 22 [18–25] 21 [18–25] 22 [19–25] 0.819
3rd trimester 19 21.11 2 15.38 17 22.08 0.728 16 26.67 2 25.00 14 26.92 1.000
Primigravidae 21 23.33 3 23.08 18 23.38 1.000 12 20.00 2 25.00 10 19.23 0.655
Number of previous pregnancies2 2 [1–3] 1 [1–3] 2 [1–2] 0.879 2 [1–3] 1 [1–5] 2 [1–3] 0.885
Illiteracy5 29 32.22 5 38.46 24 31.17 0.749 17 28.33 3 37.50 14 26.92 0.676
HIV-1 RNA (copies/mL)2 47877 [12807–
140129]
48486 [26200–
166409]
47268 [12105–
116933]
0.578 32124 [6990–
107693]
208266 [16442–
425395]
30500 [6990–
72500]
0.106
Detectable HIV-1 6 87 96.66 13 100.00 74 96.10 1.000 3 5.00 1 12.50 2 3.85 0.065
CD4+ T-cell counts (cell/mm3)2 402 [255.5–
595.5]
432 [194–576] 401 [277–596] 0.666 419 [269–654] 226 [116–285] 440 [295–664] 0.010
CD4+ T-cell counts <350 (cell/mm3) 35 38.89 5 38.46 30 38.96 1.000 23 38.33 7 87.50 16 30.77 0.008
Previous antiretroviral therapy 27 30.00 4 30.77 23 29.87 1.000 17 28.33 6 75.00 11 21.15 0.009
Characteristics at delivery
IPTp with MQ in pregnancy 7,8 42 46.67 5 38.46 37 48.05 0.564 28 46.67 4 50.00 24 46.15 1.000
HIV-1 RNA (copies/mL)2 35028 [7077–
81277]
40053 [26200–
60319]
29945 [6358–
81443]
0.667 34943 [12891–
78116]
155732 [37537–
253078]
30500 [6990–
72500]
0.024
CD4+ T-cell counts (cell/mm3)2 348 [193–566] 333 [186–559] 349 [193–584] 0.919 379 [250–584] 129 [71–5419] 440 [295–664] 0.071
CD4+ T-cell counts <350 cell/mm3
(cell/mm3)
40 44.44 6 46.15 34 44.16 1.000 25 41.67 5 62.50 19 38.46 0.259
ARV during pregnancy: -PMTCT9 73 81.11 8 61.54 65 84.42 0.057 46 81.67 4 50.00 42 84.00 0.018
- ART10 9 10.00 2 15.38 7 9.09 8 11.67 4 50.00 4 8.00
- None 8 8.89 3 23.08 5 6.49 4 6.67 0 0.00 4 8.00
MTCT 11,12 8 9.20 2 16.67 6 8.00 0.687 4 8.51 0 0.00 4 9.52 1.000
1Drug resistance mutation
2 Median (IQR)
3 Age<19 years
4 Gestational age calculated from fundal height
5 Not being able to read and/or write
6 HIV-1 RNA>400 copies/mL
7Intermittent treatment of malaria in pregnancy
8Mefloquine
9 Prevention of mother to child transmission
10Antiretroviral therapy
11 Mother to child transmission of HIV
12 Data available from 87 women at enrolment and from 47 at delivery
https://doi.org/10.1371/journal.pone.0196451.t002
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one of them (3%) developed HIVDRM to drugs included in the first-line regimen (Table 3).
Among those who developed HIVDRM, 4 (80%) had received pMTCT during pregnancy. In
addition, among women who developed HIVDRM, none transmitted HIV to their infant at
Table 3. Frequency of resistance mutations by drug category at enrolment, at delivery and acquired during
pregnancy.
Resistance category Enrolment (N = 90) Delivery (N = 60) Acquired during
pregnancy (N = 37)
n % n % n %
At least one DRM1 13 14.4 8 13.3 5 13.5
At least one NNRTI DRM2 6 6.7 5 8.3 2 5.4
At least one NRTI DRM3 8 8.9 6 10.0 2 5.4
At least one PI DRM4 2 2.2 0 0.0 1 2.7
At least one drug in first-line regime 7 7.8 6 10.0 1 2.7
1 Drug resistance mutation
2 Non-nucleoside reverse-transcriptase inhibitors
3 Nucleoside reverse-transcriptase inhibitors
4 Protease inhibitors
https://doi.org/10.1371/journal.pone.0196451.t003
Table 4. Predicted drug susceptibility in women at enrolment and at delivery.
Drug type Enrolment (N = 90) Delivery (N = 60)
Drug S1 I2 R3 S I R
NRTI4 ABC 82 (91.1%) 8 (8.9%) 0 (0%) 54 (90.0%) 5 (8.3%) 1 (1.7%)
AZT 87 (96.7%) 3 (3.3%) 0 (0%) 58 (96.7%) 2 (3.3%) 0 (0%)
DDI 86 (95.6%) 0 (0%) 4 (4.4%) 56 (93.3%) 1 (1.7%) 3 (5.0%)
D4T 83 (92.2%) 7 (7.8%) 0 (0%) 56 (93.3%) 3 (5.0%) 1 (1.7%)
FTC 82 (91.1%) 4 (4.4%) 4 (4.4%) 55 (91.7%) 2 (3.3%) 3 (5.0%)
TDF 86 (95.6%) 0 (0%) 4 (4.4%) 58 (96.7%) 0 (0%) 2 (3.3%)
3TC 82 (91.1%) 4 (4.4%) 4 (4.4%) 55 (91.7%) 2 (3.3%) 3 (5.0%)
NNRTI5 EFV 84 (93.3%) 0 (0%) 6 (6.7%) 54 (90.0%) 2 (3.3%) 4 (6.7%)
ETR 87 (96.7%) 3 (3.3%) 0 (0%) 57 (95.0%) 1 (1.7%) 2 (3.3%)
NVP 82 (91.1%) 2 (2.2%) 6 (6.7%) 52 (86.7%) 3 (5.0%) 5 (8.3%)
RPV 79 (87.8%) 9 (10.0%) 2 (2.2%) 51 (85.0%) 7 (11.7%) 2 (3.3%)
PI6 ATV/r 89 (98.9%) 1 (1.1%) 0 (0%) 60 (100%) 0 (0%) 0 (0%)
DRV/r 89 (98.9%) 1 (1.1%) 0 (0%) 60 (100%) 0 (0%) 0 (0%)
FPV/r 86 (95.6%) 3 (3.3%) 1 (1.1%) 60 (100%) 0 (0%) 0 (0%)
IDV/r 86 (95.6%) 4 (4.4%) 0 (0%) 60 (100%) 0 (0%) 0 (0%)
LPV/r 86 (95.6%) 4 (4.4%) 0 (0%) 60 (100%) 0 (0%) 0 (0%)
NFV 69 (76.7%) 20 (22.2%) 1 (1.1%) 48 (80.0%) 12 (20.0%) 0 (0%)
SQV/r 86 (95.6%) 4 (4.4%) 0 (0%) 60 (100%) 0 (0%) 0 (0%)
TPV/r 88 (97.8%) 2 (2.2%) 0 (0%) 60 (100%) 0 (0%) 0 (0%)
1 Intermediate resistance
2 Resistant
3 Susceptible
4 Nucleoside reverse-transcriptase inhibitors
5Non-nucleoside reverse-transcriptase inhibitors
6 Protease inhibitors
https://doi.org/10.1371/journal.pone.0196451.t004
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first month of age, while among those women who did not developed HIVDRM, 4 (8%) trans-
mitted HIV to their infants (p = 0.344) (S1 Table).
Table 5. HIV resistant mutations in HIV-infected pregnant women at enrolment, at delivery and acquired during pregnancy.
Type of mutation Enrolment
(N = 90)
Delivery
(N = 60)
Acquired during
pregnancy (N = 37)
All
mutations
Minority
Mutations
(freq
<20%)
All
mutations
Minority
mutations
(freq
<20%)
All
mutations
Minority
mutations
(freq
<20%)
N (%) n (%) N (%) n (%) N (%) n (%)
PR mutations1
A71T 7 (7.78) 3 (42.86) 2 (3.33) 0 (0) 0 (0) 0 (0)
A71V 3 (3.33) 2 (66.67) 0 (0) 0 (0) 0 (0) 0 (0)
D60E 20 (22.22) 3 (15.00) 12 (20.00) 1 (8.33) 0 (0) 0 (0)
G16E 11 (12.22) 4 (36.36) 11 (18.33) 4 (36.36) 0 (0) 0 (0)
I62V 12 (13.33) 2 (16.67) 6 (10.00) 1 (16.67) 0 (0) 0 (0)
I64L 4 (4.44) 0 (0) 2 (3.33) 0 (0) 0 (0) 0 (0)
I64V 2 (2.22) 2 (100.00) 0 (0) 0 (0) 0 (0) 0 (0)
K20M 3 (3.33) 2 (66.67) 0 (0) 0 (0) 0 (0) 0 (0)
K20R 32 (35.56) 3 (9.38) 24 (40.00) 1 (4.17) 1 (2.70) 0 (0)
L10I 5 (5.56) 2 (40.00) 3 (5.00) 1 (33.33) 0 (0) 0 (0)
L10V 2 (2.22) 0 (0) 3 (5.00) 1 (33.33) 0 (0) 0 (0)
L33V 1 (1.11) 0 (0) 1 (1.67) 1 (100.00) 0 (0) 0 (0)
M46I 3 (3.33) 2 (66.67) 1 (1.67) 1 (100.00) 0 (0) 0 (0)
V11I 2 (2.22) 0 (0) 1 (1.67) 0 (0) 0 (0) 0 (0)
V77I 20 (22.22) 2 (10.00) 13 (21.67) 1 (7.69) 0 (0) 0 (0)
V82I 15 (75.00) 4 (26.67) 11 (18.33) 5 (45.45) 1 (2.70) 0 (0)
Others: D30N, F53L,G48V,G73C,G73S,I50V,I54V,I64M,K20I,L10F,L76V,M46L,N88S 9 (10.00) 9 (100.00) 4 (6.67) 4 (100.00) 0 (0) 0 (0)
RT mutations2
E138A 8 (8.89) 0 (0) 4 (6.67) 0 (0) 0 (0) 0 (0)
V90I 3 (3.33) 1 (3.33) 3 (5.00) 2 (6.67) 0 (0) 0 (0)
V179D 1 (1.11) 0 (0) 3 (5.00) 2 (6.67) 0 (0) 0 (0)
V106M 1 (1.11) 1 (100.00) 2 (3.33) 1 (50.00) 1 (2.70) 1 (2.70)
M41L 1 (1.11) 1 (100.00) 1 (1.67) 1 (100.00) 0 (0) 0 (0)
M184V 3 (3.33) 0 (0) 3 (5.00) 0 (0) 0 (0) 0 (0)
M184I 1 (1.11) 1 (100.00) 1 (1.67) 1 (100.00) 0 (0) 0 (0)
K65R 4 (4.44) 4 (100.00) 2 (3.33) 2 (100.00) 1 (2.70) 1 (2.70)
K103S 0 (0.00) 0 (0) 2 (3.33) 2 (100.00) 1 (2.70) 1 (2.70)
K103N 4 (4.44) 1 (25.00) 2 (3.33) 1 (50.00) 0 (0) 0 (0)
K101E 3 (3.33) 0 (0) 2 (3.33) 0 (0) 0 (0) 0 (0)
H221Y 0 (0.00) 0 (0) 2 (3.33) 1 (50.00) 0 (0) 0(0)
G190A 3 (3.33) 0 (0) 1 (1.67) 0 (0) 0 (0) 0 (0)
E138G 4 (3.33) 2 (66.67) 1 (1.67) 0 (0) 0 (0) 0 (0)
Others: A62V, A98G,D67N,E138K,F77L,K101P,K219Q,K70R,L74V,M184I,M230I,
P225H,V106A,V108I,V75I,Y181C,Y188H,Y188L
4 (4.44) 2 (50.00) 15 (25.00) 10 (6.67) 0 (0) 0 (0)
Proportion of minority mutations were calculated as the number of mutations with a frequency under 20% among all existing mutations.
1 Protease
2 Reverse transcriptase
https://doi.org/10.1371/journal.pone.0196451.t005
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Discussion
This is the first study undertaken in Mozambique, -one of the countries with the highest preva-
lence and incidence of HIV infection in the world-, addressing HIV drug resistance in preg-
nant women and using NGS. A previous study reported NVP resistance in puerperal women
who had received sd-NVP during labor, and all other reports on HIV drug resistance were
conducted in either pediatric or adult (non-pregnant) populations [11, 21–23]. This study
showed that about 14% of women with detectable viral load at delivery had at least one
HIVDRM at enrolment, 10% even before initiating ARV drugs. On the other hand, 3% of the
women without HIVDRM at enrolment developed at least one HIVDRM to first line ARV
drugs while on pMTCT or ART during pregnancy. Thus, virological failure may occur despite
a low proportion of women with pre-existance or acquired HIVDRM, indicating that other
factors,—lack of adherence to treatment or prophylaxis, or interruptions of the ANC ‘cascade’,
may play a role in explaining the lack of viral suppression at the time of delivery in women
receiving ARV drugs during pregnancy.
The prevalence of pre-treatment HIVDRM in this study was 10%, which is higher than that
reported (5%) in a previous study carried out in adults in the capital, Maputo, and higher than
the 7% found in HIV-infected pregnant women in the south-Africa neighboring region of
Kwazulu-Natal [24]. Reports from other countries in the region show prevalences ranging
from 5% in Malawi to 12% in Tanzania [24–26]. The prevalence found here exceeds the WHO
recommended threshold of 5% transmitted HIV drug resistances at a population-level [9, 27].
Though prior to 2007, most African countries reported transmitted resistance prevalence esti-
mates of<5%, attributed mainly to low ARV drugs coverage, a trend towards increasing prev-
alence has been observed correlating with time since the initiation of ARV drugs rollout [28,
29]. However, in this study the prevalence of pre-treatment HIVDRM at enrolment may have
been over-estimated since only women with detectable viral load at delivery were selected. It is
important, to highlight that the use of an ultrasensitive genotyping in this study might have
increased the detection of HIVDRM compared to other studies using less sensitive techniques.
It is also possible that exposure to ARV drugs for pMTCT in previous pregnancies in study
participants could have favored a higher prevalence of resistance compared to the general pop-
ulation. Though differences were not significant, the proportion of multigravidae was higher
among women who did not present HIVDRM compared to those who did at enrolment, sug-
gesting that exposure to ARVs in previous pregnancies might not have been frequent among
this group. Up to the time of this study, pMTCT in low-income countries consisted of simple
regimens, which, combined with lack of virological monitoring or resistance testing, could
have fostered the emergence of HIVDRM in pregnancy [30]. Despite the long duration of
administration of sdNVP as part of pMTCT in Mozambique, HIV susceptibility to NVP was
preserved both at enrolment and at delivery in almost all study women. Although still recom-
mended in the current WHO guidelines, NVP is being phased out from first-line recom-
mended regimens. Similarly, older NRTIs such as the thymidine analogue drugs (AZT and
D4T) are being replaced by TDF as part of the NRTI backbone in first-line regimens in
resource-limited settings. Our data shows that HIV resistance to regimens used to prevent
MTCT is still very limited in the Manhic¸a district of Mozambique. Moreover, we did not
observe a major degree of selection of HIV resistance during pMTCT. Thereby, our findings
support current WHO recommendations for the region.
At enrolment, no significant differences were found between women presenting HIVDRM
and those who did not. However, among women who had HIVDRM at enrolment there was
an increased proportion of adolescents and primigravidae, whom are less likely to have been
exposed previously to ARVs, than in those with no HIVDRM. This is in line with our
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hypothesis that previous exposure to ARV drugs among study participants was low. At the
time of delivery, among women that presented HIVDRM, CD4 cell counts were lower and
mean viral load was higher compared to women with no HIVDRM. More women transmitted
HIV to their infants among those without HIVDRM despite having lower viral loads at the
time of delivery. This difference was not statistically significant and may be just due to chance
given the small numbers. Other factors favoring MTCT, such as type of delivery, breastfeeding
options or uptake of infant prophylaxis for pMTCT were not evaluated. In addition, among
the women with HIVDRM at delivery, a higher proportion had been on ART during preg-
nancy compared to those with no HIVDRM. Poor adherence to ART in those that were
already on treatment before pregnancy could explain the presence of drug resistance in this
group. In women who received pMTCT, duration of exposure to ARV drugs might have been
insufficient to promote the emergence of resistances within the current pregnancy, despite a
poor adherence.
In this study, all HIVDRM that emerged during pregnancy were minority mutants.
The clinical implications of these minority mutations on developing virological failure in these
participants cannot be identified, as all participants had virological failure at delivery as per
study inclusion criteria. However, there is evidence suggesting an association between the
minority mutations and the risk of virological failure to first-line NNRTI therapy. Similarly,
in women in low and middle-income countries (LMIC) previously exposed to NNRTI as
regimens to prevent mother-to-child transmission (pMTCT), detection of NNRTI minority
mutations also proved to be clinically relevant, also leading to increased risk of virological
failure [31–33]. Contrarily, no clinical implications have been reported in the presence of
minority resistances when PI-based regimens are used [34]. Further studies should be per-
formed for assessing the impact of current recommended drug-regimens under the Option B
+ approach.
The Mozambican national ethics review committee and the Data and Safe Monitoring
Board (DSMB) of the trial requested the investigation of the increased viral load and MTCT of
HIV in the women who received MQ compared to those who received placebo. This explains
the low number of samples in which viral RNA could be amplified, since samples were not
stored in the conditions required for this purpose. On the other hand, the limited sample size
did not allow making inferences as to whether a possible association between the administra-
tion of MQ and the development of HIVDRM during pregnancy, could have explained the
observed increased risk of MTCT in the women who received MQ. There is still insufficient
information on the potential interactions between antimalarial and ARV drugs [35, 36]. Drug
interactions could favor the selection of HIV drug resistance by reducing the plasma concen-
tration of ARV drugs to suboptimal levels. Artemether/lumefantrine for example, has been
shown to reduce significantly plasma levels of NVP [37]. In addition, the existing information
is mainly limited to artemisinin derivatives [37, 38]. A recent study reported potential pharma-
cokinetic interactions between MQ-Artesunate (MQ-AS) and lopinavir (LPV/r) in adults,
with a reduction in systemic exposure of both drug combinations, suggesting a higher risk of
treatment failure for both malaria and HIV infection when the two drugs are co-administered
[39]. Another limitation of our study was that data on adherence and on average duration of
ARV drugs administration before delivery, which are known to determine viral suppression,
was not available. Finally, as the scope of this study was focused on addressing HIVDRM in
pregnant women, NGS was not performed in HIV-infected infants. This limits the ability of
this study to inform on potential vertical transmission of HIVDRM and should be considered
when performing future studies aiming to guide maternal and pediatric care and HIV/AIDS
control strategies.
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Conclusions
The latest WHO recommendation of providing all pregnant women with lifelong ART regard-
less of CD4 count/disease stage (option B+), seems to offer important programmatic and oper-
ational advantages and thus, could accelerate progress towards eliminating new pediatric
infections. Now that global elimination of HIV pediatric infection is within our reach making
NGS accessible for HIV drug resistance surveillance also in LMICs should be a priority consid-
ering the increasing HIV-1 resistance and the limited availability of treatment options in these
settings. HIV drug resistance surveillance to evaluate the risks for selection of drug resistance
under the B+ approach should be performed alongside implementation at the country level.
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